FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.